Mesoblast reveals more COVID trials needed so shares tumble
MELBOURNE: Stem cell treatments maker Mesoblast faces a new hurdle with the US medicines regulator
MELBOURNE: Stem cell treatments maker Mesoblast faces a new hurdle with the US medicines regulator